RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:391504

Transient neonatal myasthenia gravis

medium confidenceSubtype of disorder

Also known as: NMG · Neonatal myasthenia gravis · Transient neonatal acquired myasthenia · Transient neonatal autoimmune myasthenia gravis

Publications

996

84.8th percentile

Trials

0

Interventional, condition-specific

Researchers

853

Distinct authors in sample

Gene link

CHRNG

Strong

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

Transient myasthenia gravis (MG) is a rare form of MG occurring in neonates born to mothers who have the disorder or specific circulating autoantibodies.

How rare: How common this is has not been clearly measured.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (2)

transient neonatal acquired myasthenia · transient neonatal autoimmune myasthenia gravis

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedPresent

    Strong — CHRNG

  2. LiteraturePresent

    996 matched papers (591 in last 10 years) Source

  3. Phenotype characterisedPresent

    1 HPO annotations (e.g. Transient) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPartial

    None under the specific name; 224 for broader category myasthenia gravis

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (CHRNG).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

1

Associated phenotypes · MONDO:0018326

  • Transient

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

996

996 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

996 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

591 in the last 10 years · medium confidence · 84.8th percentile (publications denominator)

Phrase hits: 229 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

853

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Eymard B10 papers · 2023

    Service de Neurologie, Hôpital de la Salpêtrière, Paris.

    Papers in Europe PMC
  2. 02
    Bach JF8 papers · 1997
    Papers in Europe PMC
  3. 03
    Morel E8 papers · 1997

    INSERM U25-CNRS UA 122, Hôpital Necker, Paris, France.

    Papers in Europe PMC
  4. 04
    Vernet-der Garabedian B6 papers · 1997

    INSERM U25, Hôpital Necker, Paris, France.

    Papers in Europe PMC
  5. 05
    Vincent A5 papers · 2023

    Department of Clinical Neurology and Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK. angela.vincent@imm.ox.ac.uk

    Papers in Europe PMC
  6. 06
    Abramsky O4 papers · 1992
    Papers in Europe PMC
  7. 07
    Brenner T4 papers · 1992
    Papers in Europe PMC
  8. 08
    Lefvert AK4 papers · 1995
    Papers in Europe PMC
  9. 09
    Chen H3 papers · 2022

    The Center for Autoimmune and Musculoskeletal Disease, The Feinstein Institute for Medical Research, 350 Community Drive, Manhasset, NY, 11030, USA.

    Papers in Europe PMC
  10. 10
    Evoli A3 papers · 2020

    Istituto di Neurologia, Policlinico A. Gemelli IRCSS, Università Cattolica del S. Cuore, Rome, Italy.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 224 trials are registered for myasthenia gravis, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

medium confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

224 interventional trials matched myasthenia gravis, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: myasthenia gravis

224

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

General rare disease registries you may be eligible for

These studies enroll across many rare conditions. They are not counted as evidence that anyone is studying this specific disease.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 4 · after dedupe 4 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 4 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (4)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Transient neonatal myasthenia gravis — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Transient neonatal myasthenia gravis" OR "Neonatal myasthenia gravis" OR "Transient neonatal acquired myasthenia" OR "Transient neonatal autoimmune myasthenia gravis") OR ("CHRNG" OR "CHRNG syndrome" OR "CHRNG-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Transient neonatal myasthenia gravis" OR "Neonatal myasthenia gravis" OR "Transient neonatal acquired myasthenia" OR "Transient neonatal autoimmune myasthenia gravis"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"myasthenia gravis"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: NMG

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T15:08:17.807Z